share_log

United Therapeutics | 10-Q: Q2 2024 Earnings Report

United Therapeutics | 10-Q: Q2 2024 Earnings Report

美国联合医疗 | 10-Q：2024财年二季报
美股SEC公告 ·  07/31 04:34

Moomoo AI 已提取核心信息

United Therapeutics reported Q2 2024 revenue of $714.9 million, up 20% YoY, with Tyvaso products leading growth at $398.2 million, a 25% increase. Net income rose to $298.9 million from $266.9 million in Q2 2023. Tyvaso DPI sales jumped 33% to $258.3 million, while nebulized Tyvaso grew 12% to $139.9 million.R&D expenses increased 57% to $139.6 million, reflecting higher spending on organ manufacturing projects and upfront licensing payments. The company's cash position remained strong at $4.3 billion as of June 30. United Therapeutics also completed a $1 billion accelerated share repurchase program during the quarter.Looking ahead, the company expects continued revenue growth from Tyvaso DPI adoption and expansion in pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients. United Therapeutics is advancing multiple clinical programs, including phase 3 trials for nebulized Tyvaso in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company also highlighted progress in its organ manufacturing initiatives, including xenotransplantation and 3D bioprinting technologies.
United Therapeutics reported Q2 2024 revenue of $714.9 million, up 20% YoY, with Tyvaso products leading growth at $398.2 million, a 25% increase. Net income rose to $298.9 million from $266.9 million in Q2 2023. Tyvaso DPI sales jumped 33% to $258.3 million, while nebulized Tyvaso grew 12% to $139.9 million.R&D expenses increased 57% to $139.6 million, reflecting higher spending on organ manufacturing projects and upfront licensing payments. The company's cash position remained strong at $4.3 billion as of June 30. United Therapeutics also completed a $1 billion accelerated share repurchase program during the quarter.Looking ahead, the company expects continued revenue growth from Tyvaso DPI adoption and expansion in pulmonary hypertension associated with interstitial lung disease (PH-ILD) patients. United Therapeutics is advancing multiple clinical programs, including phase 3 trials for nebulized Tyvaso in idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. The company also highlighted progress in its organ manufacturing initiatives, including xenotransplantation and 3D bioprinting technologies.
美国联合医疗报告了2024年第二季度的营业收入为71490万美元，同比增长20%，其中Tyvaso产品以39820万美元的销售额领先，增长25%。净利润从2023年第二季度的26690万美元上升至29890万美元。Tyvaso DPI的销售额跃升33%至25830万美元，而雾化Tyvaso的销售额增长12%至13990万美元。研发费用增加57%至13960万美元，反映出在器官制造项目和前期许可支付上的支出增加。截止6月30日，公司现金状况依然强劲，达到43亿美元。美国联合医疗在这一季度还完成了一项价值10亿美元的加速股票回购计划。展望未来，公司预计在Tyvaso DPI采用和与间质性肺病（PH-ILD）患者相关的肺动脉高压扩展方面将继续实现营业收入增长。美国联合医疗正在推进多个临床项目，包括稀有特发性肺纤维化和进行性肺纤维化的雾化Tyvaso的第三阶段临床试验。公司还强调了其在器官制造计划上的进展，包括异种移植和3D生物打印技术。
美国联合医疗报告了2024年第二季度的营业收入为71490万美元，同比增长20%，其中Tyvaso产品以39820万美元的销售额领先，增长25%。净利润从2023年第二季度的26690万美元上升至29890万美元。Tyvaso DPI的销售额跃升33%至25830万美元，而雾化Tyvaso的销售额增长12%至13990万美元。研发费用增加57%至13960万美元，反映出在器官制造项目和前期许可支付上的支出增加。截止6月30日，公司现金状况依然强劲，达到43亿美元。美国联合医疗在这一季度还完成了一项价值10亿美元的加速股票回购计划。展望未来，公司预计在Tyvaso DPI采用和与间质性肺病（PH-ILD）患者相关的肺动脉高压扩展方面将继续实现营业收入增长。美国联合医疗正在推进多个临床项目，包括稀有特发性肺纤维化和进行性肺纤维化的雾化Tyvaso的第三阶段临床试验。公司还强调了其在器官制造计划上的进展，包括异种移植和3D生物打印技术。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

独立文件6  查看翻译

独立文件7  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    SciSparc
    SPRC
    -- 0.4752
    Coeptis Therapeutics
    COEP
    -- 0.213
    X4制药
    XFOR
    -- 0.800
    Abpro Holdings
    ABP
    -- 2.960
    Anavex Life Sciences
    AVXL
    -- 13.180

    解锁榜首股票